ACE and heart failure: Publication of data from the Randomized Aldactone Evaluation Study showed that spironolactone reduced mortality by 30% compared with the mortality rate associated with placebo in patients with severe heart failure already receiving angiotensin-converting enzyme (ACE) inhibitors [6].